The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer


The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer
Slides from presentations at SABCS 2010 and transcribed comments from a recent interview with William J Gradishar, MD (1/4/11)

Dall P et al. Elderly patients in a prospective observation study on trastuzumab (Herceptin®) in the adjuvant treatment of breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract P5-12-01.

Waddell T et al. Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience. San Antonio Breast Cancer Symposium 2010;Abstract P6-11-11.

Von Minckwitz G et al. Final overall survival analysis of the TBP phase III study (GBG 26/BIG 3-05): Capecitabine vs capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment. San Antonio Breast Cancer Symposium 2010;Abstract P6-14-05.

Gruschkus SK et al. Patterns of care and outcomes of HER2 positive metastatic breast cancer patients receiving 3rd line therapy in an outpatient community setting. San Antonio Breast Cancer Symposium 2010;Abstract P3-11-15.

Dr Gradishar is Director of Breast Medical Oncology at the Robert H Lurie Comprehensive Cancer Center and Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.